enGene Holdings News

Buy Rating Justified for EnGene Holdings Amidst Strong EG-70 Prospects and Competitive Edge

TipRanks05:26 ET

EnGene to Present Details of Its Pivotal Phase 1/2 LEGEND Study of EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer With Carcinoma in Situ at the American Urology Association 2024 Annual Meeting

Oral presentation highlights rational design of EG-70 to address challenges faced by other intravesical treatment options, including preparation, handling, and safety considerations BOSTON and MONTRE

PR NewswireMay 2 16:05 ET

Express News | EnGene Holdings Inc : Wells Fargo Initiates With Overweight Rating; Price Target $30

Moomoo 24/7Apr 22 05:59 ET

EnGene Holdings Price Target Announced at $34.00/Share by Guggenheim

EnGene Holdings Price Target Announced at $34.00/Share by Guggenheim

Dow JonesApr 15 07:56 ET

Express News | enGene Holdings Inc : Rosenblatt Securities Initiates Coverage With Buy Rating and $34 Target Price

Moomoo 24/7Apr 15 07:40 ET

Press Release: Engender Announces Hiring of Dr. Raja Ruth as Senior Vice President, Urologic Oncology and Clinical Development

engender Announces Hiring of Dr. Raja Ruth as Senior Vice President, Urologic Oncology and Clinical Development Canada NewsWire BOSTON and MONTREAL, April 9, 2024 BOSTON and MONTREAL, April 9, 2024

Dow JonesApr 9 08:00 ET

EnGene Holdings Initiated at Buy by UBS

EnGene Holdings Initiated at Buy by UBS

Dow JonesMar 28 11:17 ET

UBS Initiates Coverage on EnGene Holdings With Buy Rating, $37 Price Target

UBS Initiates Coverage on enGene Holdings With Buy Rating, $37 Price Target.

MT NewswiresMar 28 11:04 ET

Buy Rating Affirmed for EnGene Holdings Amid Strong Financials and Promising Clinical Pipeline

TipRanksMar 13 01:55 ET

EnGene Holdings GAAP EPS of -$0.46

Seeking AlphaMar 12 04:33 ET

Express News | EnGene Holdings Q1 Net Loss Attributable To Common Shareholders $(10.7)M Or $(0.46) Per Share

Moomoo 24/7Mar 11 17:41 ET

EnGene Holdings 1Q Loss/Shr 46c >ENGN

EnGene Holdings 1Q Loss/Shr 46c >ENGN

Dow JonesMar 11 17:20 ET

EnGene Reports First Quarter 2024 Financial Results and Recent Corporate Progress

Pivotal phase 2 LEGEND study of EG-70 in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) remains on track with interim data anticipated...

PR NewswireMar 11 17:16 ET

EnGene Holdings Initiated at Overweight by Morgan Stanley

EnGene Holdings Initiated at Overweight by Morgan Stanley

Dow JonesMar 8 09:31 ET

Express News | Morgan Stanley Initiates Coverage On EnGene Holdings With Overweight Rating, Announces Price Target of $40

Moomoo 24/7Mar 8 09:21 ET

Buy Rating Affirmed for EnGene Holdings Amid Promising Early-Stage Data and Strong Market Prospects

TipRanksMar 8 05:16 ET

EnGene To Present at the Leerink Partners Global Biopharma Conference

Yahoo FinanceMar 5 07:00 ET

EnGene Holdings Initiated at Outperform by Leerink Partners

EnGene Holdings Initiated at Outperform by Leerink Partners

Dow JonesFeb 20 12:19 ET

Express News | Leerink Partners Initiates Coverage On EnGene Holdings With Outperform Rating, Announces Price Target of $31

Moomoo 24/7Feb 20 12:09 ET

EnGene Holdings Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 02/20/2024 87.88% Leerink Partners → $31 Initiates Coverage On → Outperform

BenzingaFeb 20 12:05 ET